Navigation Links
Gen-Probe Announces Webcast of Fourth Quarter and Full Year 2007 Earnings Conference Call
Date:1/16/2008

SAN DIEGO, Jan. 16 /PRNewswire-FirstCall/ -- Gen-Probe Incorporated (Nasdaq: GPRO) announced today that the Company will release its fourth quarter and full year 2007 financial results on Wednesday, February 13, 2008 at approximately 4:00 p.m. Eastern Time (ET). The announcement will be followed by a conference call at 4:30 p.m. ET hosted by Henry L. Nordhoff, chairman, president and chief executive officer, and Herm Rosenman, senior vice president, finance, and chief financial officer.

The conference call will be webcast live and may be accessed on the investors section of the Company's web site at http://www.gen-probe.com. An archived version of the webcast will be available on the same web site for at least 90 days. A telephone replay also will be available for 24 hours after the call ends. To access the replay, please call 800-308-7858 (U.S.) or 402-220-3841. (international).

About Gen-Probe

Gen-Probe Incorporated is a global leader in the development, manufacture and marketing of rapid, accurate and cost-effective nucleic acid tests (NATs) that are used primarily to diagnose human diseases and screen donated human blood. Gen-Probe has approximately 25 years of NAT expertise, and received the 2004 National Medal of Technology, America's highest honor for technological innovation, for developing NAT assays for blood screening. Gen-Probe is headquartered in San Diego and employs approximately 1,000 people. For more information, go to http://www.gen-probe.com.

Caution Regarding Forward-Looking Statements

Any statements in this press release about our expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by any forward-looking statement. For information about risks and uncertainties we face and a discussion of our financial statements and footnotes, see documents we have filed with the SEC, including the Form 10-Q for the period ended September 30, 2007, and all subsequent periodic filings made with the SEC. We assume no obligation and expressly disclaim any duty to update any forward-looking statement to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.

Paula Izidoro

Investor Relations

858-410-8904

paulai@gen-probe.com


'/>"/>
SOURCE Gen-Probe Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Gen-Probe to Webcast Three Upcoming Presentations
2. Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Total Revenues
3. Gen-Probe to Webcast Presentation at Bank of Americas 37th Annual Investment Conference
4. Vasogen Announces 2007 Year-End Results
5. RSB Spine, LLC Announces First Implantation of the InterPlate(TM) L for the Lumbar Spine
6. Stereotaxis Announces FDA Approval of Its Partnered Magnetic Irrigated Catheter
7. Healthcare Technologies Ltd. (NASDAQ: HCTL) Announces Extension of Letters of Intent to Acquire Majority Interest in Two Ethanol Plants
8. BioSpecifics Technologies Corp. Announces Sale of Stock in Private Placement Offering
9. Hagens Berman Sobol Shapiro Announces Proposed Class-Action Lawsuit Against CellCyte
10. Neurocrine Announces Appointment of Kevin Gorman, Ph.D., as President and Chief Executive Officer
11. Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... , Feb. 21, 2017 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or ... operational results for the three months ended December 31, 2016. ... -based life sciences and diagnostics company that develops and commercializes ... ... to build on the commercial milestones achieved in fiscal 2016," ...
(Date:2/21/2017)... ... February 21, 2017 , ... Vortex Biosciences announced ... automated benchtop system for collecting intact circulating tumor cells (CTCs) that are shed ... Medicine Tri Conference (Tri-Con) Annual Meeting 2017 (February 19–24 San Francisco). , The ...
(Date:2/21/2017)... ... 21, 2017 , ... Cancer diagnostics workflow solution provider Inspirata, ... team to lead the development and commercialization of its Cancer Information Data Trust ... and treatment of cancer. The CIDT addresses the need for curated and structured ...
(Date:2/21/2017)... ... February 21, 2017 , ... With ... operational capacity with its strategic internal leadership to provide clients with best ... operational management. With office locations in North Carolina, Massachusetts, Ohio, Illinois, ...
Breaking Biology Technology:
(Date:1/31/2017)...  Spero Therapeutics, LLC, a biopharmaceutical company founded ... bacterial infections, today announced it has acquired a ... Bono Bio Ltd (PBB) to bolster its pipeline ... of Gram-negative bacteria.   The assets acquired have been ... group company. "The acquisition of these ...
(Date:1/24/2017)... , Jan. 24, 2017 Biopharm Reports ... the laboratory use of nuclear magnetic resonance spectroscopy ... end-users and profiled current practices, developments, trends and ... well as growth and opportunities. These areas include ... NMR instruments, needs and innovation requirements, hyphenated NMR ...
(Date:1/19/2017)... , Jan. 19, 2017 ... user experience and security for consumer electronics, and ... payment processing systems and cybersecurity solutions, today announced ... enterprises and financial institutions worldwide to bolster security ... the end-to-end secure user authentication platforms they offer, ...
Breaking Biology News(10 mins):